source
- Argenx to acquire macrocycle biotech Unnatural Products in up to $1.15 billion dealArgenx announced Monday it will acquire Unnatural Products, a biotech focused on macrocycle therapeutics that began as a garage startup. The transaction is structured as an up-to-$1.15 billion dea…
- Zura reports Phase 2 flop in painful skin disorder; stock nosedivesA small biotech’s stock collapsed after the company reported a Phase 2 failure in a debilitating skin condition. Zura Bio said Monday morning that both doses of its experimental drug tibulizumab fa…Endpoints · 33m ago↗ source